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Abstract
Background: Differentiation therapy has been shown effective in treatment of several types of cancer cells and
may prove to be effective in treatment of glioblastoma multiforme, the most common and most aggressive
primary brain tumor. Although extensively used as a reagent to inhibit protein synthesis in mammalian cells,
whether cycloheximide treatment leads to glioma cell differentiation has not been reported.
Methods: C6 glioma cell was treated with or without cycloheximide at low concentrations (0.5-1 μg/ml) for 1, 2
and 3 days. Cell proliferation rate was assessed by direct cell counting and colony formation assays. Apoptosis was
assessed by Hoechst 33258 staining and FACS analysis. Changes in several cell cycle regulators such as Cyclins D1
and E, PCNA and Ki67, and several apoptosis-related regulators such as p53, p-JNK, p-AKT, and PARP were
determined by Western blot analysis. C6 glioma differentiation was determined by morphological characterization,
immunostaining and Western blot analysis on upregulation of GFAP and o p-STAT3 expression, and upregulation
of intracellular cAMP.
Results: Treatment of C6 cell with low concentration of cycloheximide inhibited cell proliferation and depleted
cells at both G2 and M phases, suggesting blockade at G1 and S phases. While no cell death was observed, cells
underwent profound morphological transformation that indicated cell differentiation. Western blotting and
immunostaining analyses further indicated that changes in expression of several cell cycle regulators and the
differentiation marker GFAP were accompanied with cycloheximide-induced cell cycle arrest and cell differentiation.
Increase in intracellular cAMP, a known promoter for C6 cell differentiation, was found to be elevated and required
for cycloheximide-promoted C6 cell differentiation.
Conclusion: Our results suggest that partial inhibition of protein synthesis in C6 glioma by low concentration of
cycloheximide induces cell cycle arrest at G1 and M phases and cAMP-dependent cell differentiation.
Background
Glioblastoma multiforme (GBM) is the most common
central nervous system malignancy, whose highly inva-
sive and diffuse nature leaves rare opportunity for cure.
Despite aggressive surgical approaches, optimized radia-
tion therapy regimens and the application of cytotoxic
chemotherapies, the median survival rates from time of
diagnosis range from 12-15 months [1].
Differentiation, as apoptosis, is a defense mechanism
by which mammalian cells guard against tumorigenesis.
Differentiation therapy, using agents that promote can-
cer cell differentiation, has been shown to be effective in
vitro and in vivo in treatment of several types of cancer
cells [2]. Thus, neuroblastoma cells were shown to
undergo terminal differentiation upon elevation of intra-
cellular adenosine 3’,5 ’-cyclic monophosphate (cAMP)
concentration after treatment with cyclic nucleotide
phosphodiesterase inhibitors or adenylate cyclase activa-
tors [3-7]. Cholera toxin was reported to induce malig-
nant glioma cell differentiation via the PKA/CREB
pathway [8]. Differentiation of glioma cells can also be
achieved by treatment of cells with Datura stramonium
agglutinin [9]. Notably, all-trans-retinoic acid has been
used as an agent to induce cell differentiation in clinical
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[10,11], demonstrating the remarkable efficacy of differ-
entiation therapy in treatment of cancers.
Cycloheximide (CHX), originally isolated from Strepto-
myces griseus, has been widely used as an experimental
tool to analyze the contribution of protein synthesis to
the intracellular signaling and associated cellular func-
tion. It inhibits protein translation in mammalian cells
at multiple steps, with a particular potency on transla-
tion initiation [12]. Protein synthesis consumes enor-
mous energy and resources in cells especially in fast
growing cancer cells, and inhibition of protein synthesis
by CHX, even in a relatively mild situation, may consti-
tute a major blockade to the cellular functions such as
cell proliferation. Indeed, inhibition of synthesis of spe-
cific proteins by CHX, such as c-Myc [13], p27 [14] has
been interpreted as evidence for the necessity of those
cell cycle regulators in either cell proliferation or cell
cycle arrest. Similarly, CHX has been shown to either
block [15-17] or promote [18-20] gene expression-
dependent cell death in different types of cells and
experimental paradigms. Surprisingly, a possible biologi-
cal effect of CHX in cancer therapy, to our knowledge,
has never been investigated.
In the present study, we show that low concentration
of CHX (LCC) potently inhibited C6 cell proliferation
and depleted cells at both G2 and M phases, suggesting
blockade at G1 and S phases during which massive pro-
tein accumulation is required. Surprisingly, treatment of
C6 cell with LCC also induced dramatic morphological
transformation that is indicative of cellular differentiation;
this change was accompanied by upregulation of differen-
tiation marker glial fibrillary acidic protein (GFAP). In
addition, we found that intracellular cAMP levels were
dramatically increased in C6 cells treated with LCC, and
that this elevated intracellular cAMP is responsible for
C6 cell differentiation and upregulation of GFAP.
Methods
Cell culture and reagents
Rat C6 glioma cell (ATCC cat. number CCL-107) was
cultured in DMEM (Invitrogen) containing 10% FBS
(Atlanta Biologicals). Cycloheximide (C4859, CHX),
8-(4-Chlorophenylthio) adenosine 3’,5 ’-cyclic monopho-
sphate sodium salt (C3912, 8-pCPT-cAMP) and Adeno-
sine (A9251, Ado) were obtained from Sigma. Sources
of the antibodies and dilutions are as follows: GFAP
(#3670, 1:1000 for both Western and immunostaining),
p-Akt (#9271, 1:1000), Cleaved Caspase-3 (Asp175)
(1:1000) were from Cell signaling Technology. PARP
(P76420, 1:1000) from BD Biosciences. p-JNK (sc-6254,
1:1000), p-Stat3 (sc-7993, 1:1000), Cyclin D1(R-124,
1:1000), Cyclin E (sc-481, 1:750), PCNA (sc-56, 1:500),
p-IB-a (sc-101713, 1:1000), p53 (sc-98, 1:1000), and
Ki67 (sc-7846, 1:500) from Santa Cruz Biotechnology.
The materials and experimental procedures used in this
research were approved by the Biosafety and Recombi-
nant DNA Committee (BRDC) at Penn State University
Hershey Medical Center.
Morphological observations
C6 cells were plated in 6-well plates at a density of
1×10
5 per well. Cells were incubated in culture medium
containing CHX and/or other reagents at indicated con-
centrations. Photographs of cells were taken 24 h later.
Proliferation assay
C6 cells were seeded into 6-well plates at a density of
5×10
5 per well and were treated as indicated. Cells were
collected after trypsin digestion and counted with a
hemocytometer. Values in proliferation charts are
expressed as means ± SEM (n = 3).
Colony formation assay
C6 cells were seeded in 35 mm culture dish at 1,000
cells per dish. After indicated treatment, cells were
stained with 0.5% crystal violet solution (made in 25%
methanol and stored at room temperature) for 10 min
and photographed.
Flow cytometry
Cell flow cytometry analysis was done as described pre-
viously [21]. At the indicated time, cells were trypsi-
nized, washed twice with 1×PBS, and pelleted by low
speed centrifugation. Pellet was resuspended with 70%
ethanol for 30 min at 4°C. Cells were spun down and
were incubated with the DNA-binding dye propidium
iodide (PI) solution [0.1% sodium citrate (w/v), 0.1% Tri-
ton X-100 (v/v), and 50 mg/L PI in deionized water] for
1 hour at room temperature. Finally, cells were analyzed
by a FACS caliber flow cytometer.
Immunocytochemical staining and confocal microscopy
Experiments were carried out as in [17]. Briefly, cells
grown on coverslips were treated as indicated and then
fixed in methyl alcohol at -20°C for 10 min. Samples
were blocked for 1 h with 5% BSA and then incubated
for 1 h at 37°C with the Anti-GFAP antibody. A goat
anti-rabbit IgG-TR (Santa Cruz) secondary antibody was
used for specific detection of anti-GFAP. Nuclei were
stained with Hoechst 33258.
SDS-PAGE and immunoblotting
Cells in the culture dish were washed with ice-cold PBS
and lysed in ice-cold RIPA buffer [50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0,5% sodium deoxycholate, 0.1%
SDS, 1% Nonidet P40]. Cell extracts preparation and
Western blotting analysis were done as previously [22].
Liu et al. BMC Cancer 2010, 10:684
http://www.biomedcentral.com/1471-2407/10/684
Page 2 of 8Determination of intracellular cAMP level
C6 cells (2 × 10
5) were seeded in 24-well. After over-
night culturing, the cells were treated with CHX, CHX
and Ado, at indicated concentrations, and vehicle con-
trol for 24 hours. Cells were lysed in 200 μlo f0 . 1M
HCl and cell extracts were collected after removing cell
debris by centrifugation. Quantification of cAMP was
carried out using a kit (BioVision) following manufac-
turer’s instruction. Three independent measurements
were done for each treatment. cAMP level in untreated
C6 cells was arbitrarily set at 1. Data are presented as
means ± SEM (n = 3).
Results
Potent inhibition of C6 glioma cell proliferation by LCC
To see how C6 cell responds to CHX treatment, we
performed a dose-response analysis in 6-well plates
using CHX concentration ranging from 0 to 100 μg/ml
(1 μg/ml = 3.5 μM). High concentration of CHX (50-
100 μg/ml) prompted cell death in a few hours (data
not shown). LCC (0.1-10 μg/ml) did not cause cell
death, permitting us to examine C6 cell response over
longer period of time. As shown in Figure 1A, dramatic
morphological transformation was observed among the
C6 cells after treatment with 1 μg/ml CHX for 24 h;
cells were no longer flat, but rather were spindle-
shaped with processes (Figure 1A). No cell death was
detectable above the background for several days as
indicated by Hoechst 33258 staining (data not shown),
although the nuclei of the C6 cells treated with CHX
were uniformly smaller (Figure 1A). These CHX-trea-
ted cells seemed to cease proliferation completely; a
cell proliferation assay showed that the normally fast-
growing C6 cell no longer proliferated when treated
with LCC (Figure 1B). We additionally performed col-
ony-formation assay showing that LCC was extremely
potent in inhibiting C6 cell proliferation (Figure 1C).
T h ee x p e r i m e n t sd e s c r i b e di nF i g u r e1 Ba n d1 Ca l s o
demonstrated a dose-dependent response and indicated
that the IC50 for CHX to inhibit C6 proliferation was
less than 0.5 μg/ml.
To see whether cessation of C6 cell proliferation is
accompanied with changes in cell proliferation markers
and cell cycle regulators in response to LCC, we pre-
pared cell extracts from C6 cells untreated or treated
with CHX (0.5 μg/ml) for 24 or 48 h and carried out
western blotting analysis. As shown in Figure 1D, cell
proliferation markers Ki67 and PCNA and cell prolifera-
tion regulators cyclin D1 and cyclin E were all downre-
gulated. Taken together, these data showed that LCC
suppresses the expression of several cell cycle markers
and stimulators in C6 cell and potently block C6 cell
proliferation.
LCC does not induce apoptosis in C6 cell but depletes
cells at G2 and M phases
CHX has been shown to either block [15-17] or induce
[18-20] gene expression-dependent cell death in differ-
ent types of cells and experimental paradigms. In con-
trast to high concentration of CHX (50-100 μg/ml),
which caused death of C6 cells within 6 hours, LCC
(0.1-10 μg/ml) did not show any impact on C6 cell sur-
vival (Figure 1A); a direct count of the percentage of
cell death showed no difference between control and
LCC-treated C6 cells (data not shown). We next carried
out FACS analysis on C6 cells treated with various LCC.
As shown in Figure 2A-D, no sub-G1 population was
observed in cells treated with up to 10 μg/ml CHX,
further confirming the non-apoptotic effect of LCC on
C6 cell. While CHX treatment did not alter the percen-
tage of cells in G1 and S phases, it surprisingly depleted
the G2/M population in a dose-dependent manner. We
interpret the results to indicate that LCC blocked C6
cell proliferation at both G1 and S phases, which is con-
sistent with the expectation that progression of both G1
and S phases require high level of protein synthesis.
We additionally examined expression of several mole-
cules involved in cell survival and death regulation. As
shown in Figure 2E, most of these molecules such as p-
Akt and p53 either did not change or underwent changes
that in fact favor cell survival. Therefore, we concluded
that LCC is not apoptotic to C6 cell, instead it blocks C6
cell cycle progression at the G1 and S phases.
LCC promotes reversible differentiation of C6 glioma cell
The morphological transformation (Figure 1A) and ces-
sation of proliferation (Figure 1B, C) of C6 cells in
response to LCC suggested that C6 cells might undergo
a process of differentiation. Indeed, as shown in Figure
3A, the smaller and spindle-shaped cells formed after
treatment of CHX were remarkably similar to those
treated with 8-CPT-cAMP, an analog of cAMP that is
known to induce C6 cell differentiation [23,24]. Immu-
nostaining of C6 cells with GFAP, a reliable marker for
gliogenesis, indicated a dramatic increase in GFAP pro-
duction in C6 cells treated with CHX (1 μg/ml) (Figure
3B). This increased expression of GFAP was observed
with CHX concentrations ranging from 0.5-10 μg/ml
and at comparable levels to 8-CPT-cAMP (cAMP) treat-
ment (Figure 3C), and with highest expression observed
at 1 d post treatment (Figure 3D). These data thus
showed that C6 cell differentiation induced by LCC is
similar to that induced by cAMP. In addition, we
demonstrated that the increase of GFAP in C6 cells
treated with CHX was accompanied with a measurable
increase in p-STAT3 (Figure 2E), which is an obligatory
transcription activator for GFAP [25,26].
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differentiation can be reversed upon CHX withdrawal.
We found that differentiated C6 cells reversed their dif-
ferentiation phenotype and resumed proliferation within
1 d of CHX removal (data not shown). Taken together,
the evidence indicated that LCC is able to block
cell proliferation and induce reversible differentiation in
C6 cell.
CHX-promoted C6 cell differentiation is associated with
an increase in intracellular cAMP and can be blocked by
adenosine
Since CHX has been shown to induce increases in intra-
cellular cAMP in several types of cells including neuro-
blastoma and glioma [27], and cAMP or its analogs are
effective inducers of differentiation in C6 glioma cell
[23,24](Figure 3A), we hypothesized that LCC promote
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Figure 1 LCC potently inhibits C6 glioma cell proliferation. A) C6 cells were seeded in 6-well plates and treated without or with CHX (1 μg/ml)
for 48 h. For observation of the integrity of nuclei, cells were stained with Hoechst 33258 and visualized under fluorescence microscope. Both phase
contrast (left panels) and fluorescent (right panels) photos were shown (magnification: ×200). B) C6 cells were seeded in 6-well plates at a density of
1.0×10
5 per well. CHX were added at concentration of 0 (◆) (as control), 0.5 μg/ml(■), and 1 μg/ml(▲), as indicated. Cells were collected in each of the
next 3 days after trypsin treatment and cell numbers were counted using a haemocytometer. Data are presented as means ± SEM (n = 3). C) Colony
Formation Efficiency Assay. 1,000 cells were plated in 35-mm tissue culture dishes. After overnight culturing, cells were exposed to different doseso f
CHX: (a) control; (b) CHX 0.1 μg/ml; (c) CHX 0.5 μg/ml; (d) CHX 1 μg/ml. Photos were taken 6 days later after staining with 0.5% crystal violet. d)
Western immunoblotting analysis on cell cycle regulators and indicators. C6 Cells were cultured in 6-well plates and were treated without or with CHX
(0.5 μg/ml) for indicated time. Western blotting was performed as described in the Methods.
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lar cAMP in C6 cells. To test this hypothesis, we ana-
lyzed the intracellular cAMP in C6 cells untreated or
treated with CHX (10 μg/ml). Our data indicated that
C6 cell intracellular cAMP concentration increased 5-
fold in response to CHX treatment (Figure 4A). To see
whether CHX-induced intracellular cAMP increase is
responsible for CHX-promoted differentiation transfor-
mation, we cotreated C6 cells with CHX and adenosine
(Ado) (100 μM), a known inhibitor for cAMP synthesis
[28], to reduce intracellular cAMP. As shown in Figure
4 A ,B ,c o t r e a t m e n to fC 6c e l l sw i t hA d ob l o c k e d
CHX-induced increase in intracellular cAMP in C6 cells
(Figure 4A) and prevented CHX-promoted C6 cell phe-
notypic change of differentiation (Figure 4B). Interest-
ingly, Ado alone did not cause any discernible effect on
C6 cell; and it did not block CHX-promoted cessation
of C6 cell proliferation (Figure 4B and data not shown).
We additionally found that CHX-induced GFAP expres-
sion could be effectively blocked by Ado treatment (Fig-
ure 4C) and CHX-induced cell proliferation was not
reversed with cotreatment of Ado (Figure 4D). Taken
together, these data indicated that CHX-induced
increase in intracellular cAMP in C6 cells is responsible
f o rC H X - p r o m o t e dC 6c e l ld i f f e r e n t i a t i o na n dt h a tt h e
underlining mechanism for CHX-induced cell cycle
arrest and that for CHX-induced cell differentiation are
independently regulated and separable.
Discussion
CHX is a potent inhibitor of protein translation in
mammalian cells and is widely used in probing the
molecular mechanism of various biological processes.
While high concentration of CHX (100 μM) was shown
to induce apoptosis in hepatocytes both in vitro [20]
and in vivo [19], and we found that high concentration
of CHX (50-100 μg/ml, or 180-360 μM) kills C6 cells in
a few hours (data not shown), LCC (0.1-10 μg/ml), with
an IC50 at below 0.5 μg/ml, arrested C6 cell proliferation
(Figure 1 and 2) and promoted cell differentiation (Fig-
ure 3). Although it was not the focus of this study to
identify the critical proteins that are involved in each of
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Figure 2 LCC does not induce apoptosis in C6 cell but depletes cells at G2 and M phases. A-D) The effect of CHX on cell cycle profile was
examined by flow cytometry analysis. C6 cells were seeded in 10 cm dishes at a density of 1.0 × 10
6 per dish. After treatment with CHX at
indicated concentration for 24 h, cells were trypsinized, washed twice by PBS, and fixed with ice-cold 70% ethanol. DNA content was measured
after stained by PI solution [0.1% sodium citrate (w/v), 0.1% Triton X-100 (v/v), 50 mg/ml PI in demonized/distilled water]. Percentages of G2/M
(G2) phase cells were indicated. E) Western immunoblotting analysis on molecules that are regulators and indicators of cell stress and cell death.
Experiments were done as in Figure 1D.
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Page 5 of 8the biological processes, the more-than-100-fold dispar-
ity in CHX concentrations required for induction of C6
cell death and for C6 cell cycle arrest and differentiation
indicated a fundamental difference in the requirement
for C6 cell survival, proliferation, and differentiation.
We speculated that when C6 cell encounters LCC that
shut off the production of a fraction of protein popula-
tion in the cell, the first to be affected and thus most
sensitive to CHX inhibition are the ones that are for cell
proliferation. In this situation, C6 cell even increases the
production of selective proteins such as GFAP (Figure
3) and c-fos and c-jun [29] that may be needed for dif-
ferentiation. With increasing concentration of CHX,
however, synthesis of proteins whose function involves
cell survival, which is more fundamental and strategic to
the cell in the long run, will be affected. Thus, the dif-
ferential response of C6 cell to low and high concentra-
tion of CHX may indicate the presence of a priority
hierarchy for protein production in C6 cell. Interest-
ingly, we also found that CHX induces U251 human
glioma differentiation (data not shown). However, the
CHX concentration that is required for U251 to
differentiate (10 μg/ml) is about 10 times higher, possi-
bly due to cellular difference in CHX sensitivity or in
permeability.
We observed downregulation of a number of cell cycle
regulators in C6 cell treated with LCC (Figure 1D),
which is generally consistent with the outcome of cell
cycle arrest. In addition, we found that p53 is downre-
gulated in C6 cell treated with LCC (Figure 2E). This
may explain the fact that apoptosis is not activated in
these cells. With regard to differentiation, we saw strong
increases in GFAP, a reliable indicator for glial differen-
tiation, both in immunostaining and in Western blotting
analyses (Figure 3B, C and 3D). In addition, the increase
of GFAP was accompanied with an increase in p-
STAT3 (Figure 3E), which is an obligatory transcription
activator for GFAP [25,26]. These data convincingly
demonstrated that partial blockade of protein synthesis
drives forward the differentiation process in C6 glioma
cell. Previously, it was shown that C6 cell differentiates
when treated with cholera toxin [8] and that other neuro-
blastomas and glioma also differentiate after treated with
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Figure 3 LCC induces C6 cell differentiation. A) LCC promotes
morphological transformation of C6 cells that indicated cell
differentiation. C6 cells were exposed to CHX at indicated
concentration and to 8-cpt-cAMP (100 μM) for 24 h. Photos were
taken as in Figure 1A (magnification, ×200). B-D) Treatment of C6
cells with LCC upregulates GFAP. In B), C6 cells cultured for 12 h in
the absence (upper panels) or presence (lower panels) of CHX (1
μg/ml) were either photographed directly (left panels) or
immunostained for GFAP (red) as described in Materials and
Methods. Nuclei were stained with Hoechst 33258 as in Figure 1A.
In C and D), GFAP expression was assessed in Western
immunostaining analysis. Cells were treated with CHX at indicated
concentration for 24 h (C) or 24 and 48 h (D). b-actin was used as
loading control. E) Western blotting was done as in D) except anti-
p-STAT3 was used. b-actin was used as loading control.
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Figure 4 LCC upregulates intracellular cAMP in C6 cells and
this is required for CHX-induced C6 cell differentiation.A )
Treatment of C6 cells with LCC elevated intracellular cAMP and
cotreatment with Adenosine (Ado) blocked CHX effect. Experiments
were carried out as described in Methods. Data are presented as
means ± SEM (n = 3). * p < 0.01 (0 vs. 10 μg/ml CHX); ** p < 0.001
(10 μg/ml CHX with Ado vs. 10 μg/ml CHX without Ado). B)
Adenosine blocked CHX-induced C6 morphological transformation.
C6 cells (1.0×10
5 per well) were preincubated with or without Ado
(100 μM) for 1 h and then cotreated with or without CHX (1 μg/ml)
for 24 h as indicated. Phase contrast photos were taken as in Figure
1A. C) Adenosine blocked CHX-induced GFAP upregulation. Western
immunostaining was carried out as in Figure 3C except cells were
pretreated with or without Ado followed with cotreatment with or
without CHX (1 μg/ml) and Ado for 24 h. D) Cell cycle arrest
induced by CHX was not affected by Adenosine. Experiments were
done as in Figure 1B except cells were pretreated with or without
Ado. Data are presented as means ± SEM (n = 3).
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late cyclase activators [3-7]. These are in line with our
findings that LCC upregulated intracellular concentration
of cAMP by 5-fold (Figure 4A) and that the increase in
intracellular cAMP is required for CHX-induced C6 cell
differentiation (Figure 4B, C). These results argue that
CHX employs the classical cAMP pathway to inhibit C6
cell proliferation and promote cell differentiation and that
intracellular cAMP is a major intermediate that governs
glioma cell proliferation and differentiation.
Current therapies used to treat cancer are highly toxic
and often nonspecific. Differentiation therapy could be a
potentially valuable strategy [2]. In this regard, all-trans-
retinoic acid has been shown to be remarkable efficient
to induce APL cell differentiation in clinical settings
[10,11]. Since C6 cell is a well-established cell line for
study on tumorigenesis, cancer cell proliferation and dif-
ferentiation, our data showing that LCC induces C6 cell
cycle arrest and cell differentiation will have important
impact on the strategy of cancer differentiation therapy.
Conclusions
Several important conclusions came out from this study.
First, unlike high concentration of CHX that provokes C6
cell death in a few hours, LCC is not lethal to C6 cell
even after several days of treatment; it causes cell cycle
arrest at G1 and S phases during which large amount of
proteins, and many of them being critical for cell cycle
progression, are synthesized. Second, LCC promotes a
profound morphological transformation that indicates C6
cell differentiation, which is further supported by the
observation that the expression of glial differentiation
marker GFAP is dramatically upregulated. Third, LCC
dives forward the C6 cell differentiation process by mobi-
lizing a classical pathway that involves upregulation of
intracellular concentration of cAMP. Forth, LCC seems
to illicit multiple biological effects in C6 cell, which
include cell cycle arrest and cell differentiation, by
mechanisms that are clearly distinct and separable. For
instance, LCC-promoted C6 cell differentiation but not
cell cycle arrest can be reversed by blockade of upregula-
tion of intracellular cAMP; and Ado-induced downregu-
lation of intracellular cAMP, per se, does not inhibit C6
cell proliferation. Since CHX is one of the most used
reagents in molecular and cellular biology research and
C6 cell is a well-established cell line to study cancer cell
proliferation, apoptosis, and differentiation, our findings
reported here is likely to have a wide implication to
future studies in these related fields.
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